injection of bevacizumab

Phase 2Monoclonal antibody

SShahid Beheshti University of Medical Sciences

injection of bevacizumab is one of 2 small molecule programs targeting Advanced Hepatocellular Carcinoma (HCC). It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Advanced Hepatocellular Carcinoma (HCC)Recruiting

Advanced Hepatocellular Carcinoma (HCC)Phase 2

Recruiting

Competition

Competitive Landscape

1 competitor in Advanced Hepatocellular Carcinoma (HCC)

#DrugCompanyPhaseTrials

WGI-0301

ZZhejiang Haichang Biotech Co., Ltd.

Phase 2

2 2

injection of bevacizumab

SShahid Beheshti University of Medical Sciences

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2028

Phase 2Recruiting

Advanced Hepatocellular Carcinoma (HCC)

NCT06737913

Clinical

Trials by Indication[1]

Diabetic Macular Edema1 trial

The Effect of Intravitreal Erythropoietin Injection for Refractive Diabetic Macular Edema

Unknown status·SShahid Beheshti University of Medical Sciences·Phase 2/3·NCT03821168·58 enrolled

Retinal Vein Occlusion1 trial

Combined Intravitreal Injection of Bevacizumab and Fasudil Versus Bevacizumab Alone for Macular Edema Secondary to Retinal Vein Occlusion in Previously Treated Patients

Unknown status·SShahid Beheshti University of Medical Sciences·Phase 2/3·NCT03391219·36 enrolled

Advanced Hepatocellular Carcinoma (HCC)1 trial

Hepatic Arterial Infusion or Intravenous Infusion of Adebrelimab, Combined With Bevacizumab and Hepatic Arterial Infusion of FOLFOX Chemotherapy for Advanced Hepatocellular Carcinoma: a Multicenter, Open Label, Randomized Phase II Trial

Recruiting·SSun Yat-sen University·Phase 2·NCT06737913·76 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for injection of bevacizumab. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — injection of bevacizumab compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for injection of bevacizumab. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Shahid Beheshti University of Medical Sciences company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Monoclonal antibody[2]
Highest Phase: Phase 2[1]
Company: SShahid Beheshti University of Medical Sciences

injection of bevacizumab

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2028

Trials by Indication[1]

Diabetic Macular Edema1 trial

Retinal Vein Occlusion1 trial

Advanced Hepatocellular Carcinoma (HCC)1 trial

References

Drug Info

Quick Facts

Related News